Marksans Pharma Limited (NSE:MARKSANS)

Market Cap	110.03B
Revenue (ttm)	26.23B
Net Income (ttm)	3.81B
Shares Out	453.16M
EPS (ttm)	8.40
PE Ratio	28.90
Forward PE	22.59
Dividend	0.80 (0.33%)
Ex-Dividend Date	Sep 17, 2024

Volume	154,476
Average Volume	1,258,675
Open	243.50
Previous Close	242.80
Day's Range	241.80 - 246.00
52-Week Range	158.22 - 358.70
Beta	1.38
RSI	45.57
Earnings Date	May 30, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 1,141
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MARKSANS

Financial Performance

In 2024, Marksans Pharma's revenue was 26.23 billion, an increase of 20.46% compared to the previous year's 21.77 billion. Earnings were 3.81 billion, an increase of 21.32%.